Letter to the Editor | Published:

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Leukemia volume 30, pages 995998 (2016) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , , , , , et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.

  2. 2.

    , , , , , et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

  3. 3.

    , , , , , et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014; 99: 232–242.

  4. 4.

    , , , , , et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679–686.

  5. 5.

    , , , , , et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119: 4375–4382.

  6. 6.

    , , , , , et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23: 1337–1341.

  7. 7.

    , , , , , et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075–2085.

  8. 8.

    , , , , , et al. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther 2013; 38: 41–47.

  9. 9.

    , , , , , et al. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori 2013; 99: e193–e202.

  10. 10.

    , , , . Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist 2013; 18: 37–45.

  11. 11.

    , , . Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011; 364: 2365–2366.

  12. 12.

    , , , , , et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28: 4635–4641.

  13. 13.

    , , , , , et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976–4984.

  14. 14.

    , , , , , et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431–440.

  15. 15.

    , , , , , et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116: 4745–4753.

  16. 16.

    , , , , , et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100–2105.

Download references


The authors would like to thank Mark Yap and Shanmugapriya Saravanan of McKesson Specialty Health for their support with data collection for this analysis. The authors would also like to thank Iwen Pan of McKesson Specialty Health, Rahul Dhanda, formerly of McKesson Specialty Health, and Abbie Ba-Mancini of Millennium Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, for their input into the study design and preliminary analysis. The authors would like to acknowledge Steve Hill of FireKite, an Ashfield company, part of UDG Healthcare plc, for writing support during the development of this manuscript, which was funded by Millennium Pharmaceuticals Inc and complied with Good Publication Practice 2 ethical guidelines (Graf et al., BMJ 2009). This research was sponsored by Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Author contributions

SKK and EM designed the research. SKK, AEE, FKB, MQL, AD, MSD, M-HL, PL, WYC, KD, DR, DP and SVR performed the research. EM, AEE, MSD, M-HL, PL, WYC, KD, DR and DP collected data. MSD, M-HL, PL, WYC and KD performed statistical analysis. SKK, EM, MSD, M-HL, PL, WYC, KD, DR, DP, LN and MQ analyzed and interpreted data. SKK and EM wrote the manuscript. All authors reviewed and revised the draft manuscript, and reviewed and approved the final version for submission.

Author information


  1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    • S K Kumar
    • , A E Engebretson
    • , F K Buadi
    • , M Q Lacy
    • , A Dispenzieri
    •  & S V Rajkumar
  2. Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

    • E Ma
    • , L Niculescu
    •  & M Quick
  3. Analysis Group, Inc, Boston, MA, USA

    • M S Duh
    • , M-H Lafeuille
    •  & W Y Cheng
  4. Groupe d’analyse, Ltée, Montreal, QC, Canada

    • P Lefebvre
    •  & K Dea
  5. McKesson Specialty Health, The Woodlands, TX, USA

    • D Rembert
    •  & D Patt


  1. Search for S K Kumar in:

  2. Search for E Ma in:

  3. Search for A E Engebretson in:

  4. Search for F K Buadi in:

  5. Search for M Q Lacy in:

  6. Search for A Dispenzieri in:

  7. Search for M S Duh in:

  8. Search for M-H Lafeuille in:

  9. Search for P Lefebvre in:

  10. Search for W Y Cheng in:

  11. Search for K Dea in:

  12. Search for D Rembert in:

  13. Search for D Patt in:

  14. Search for L Niculescu in:

  15. Search for M Quick in:

  16. Search for S V Rajkumar in:

Competing interests

Dr Kumar has acted as a consultant for Merck, Celgene, Millennium Pharmaceuticals, Inc and Onyx; and has received research funding from Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Celgene, Novartis, Genzyme, Onyx and Cephalon. Ms Ma, Dr Niculescu and Dr Quick are employees of Millennium Pharmaceuticals, Inc. Dr Lacy has received research funding from Celgene Corporation. Dr Dispenzieri has received research funding from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Pfizer, Celgene Corporation and Janssen. Dr Duh, Ms Lafeuille, Mr Lefebvre, Ms Cheng and Ms Dea have received research funding from Millennium Pharmaceuticals, Inc, via engagement with employer Analysis Group Inc. Dr Rembert and Dr Patt are employees of McKesson Specialty Health Ms Engebretson, Dr Buadi and Dr Rajkumar declare no conflict of interest.

Corresponding author

Correspondence to S K Kumar.

About this article

Publication history




Further reading